immune system
• 7-fold to 20-fold less found in serum 2 hours after dosing with LPS, CpG, or IL-1
|
• 5-fold to 100-fold less found in serum 2 hours after dosing with LPS, CpG, or IL-1
|
• reduced production by plasmacytoid DCs in response to ligands for TLR-7 and -9
|
• reduced production of IFN-alpha by macrophages in response to ligands for TLR-7 and -9
• reduced production of IFN-alpha by dendritic cells in response to influenza virus
|
• reduced production of IFN-beta by macrophages in response to ligands for TLR-7 and -9
• reduced production of IFN-beta by dendritic cells in response to influenza virus
|
• reduced production by macrophages in response to TLR ligands except for a ligand to TLR3
• reduced production of IFN-alpha and IFN-beta by dendritic cells in response to influenza virus
|
• reduced production by macrophages in response to TLR ligands except for a ligand to TLR3
• reduced production of IFN-alpha and IFN-beta by dendritic cells in response to influenza virus
|
• resistant to LPS- and CpG- induced shock
|
• no lethality when injected with a high dose of LPS or CpG
|
homeostasis/metabolism
• 7-fold to 20-fold less found in serum 2 hours after dosing with LPS, CpG, or IL-1
|
• 5-fold to 100-fold less found in serum 2 hours after dosing with LPS, CpG, or IL-1
|